In children with severe eczema, targeted treatment boosts growth
A study from Trinity College Dublin found that children with severe eczema often experience growth restriction. Treatment with the biologic drug dupilumab was shown to significantly improve height in these children compared to those who did not receive the medication.
Why it matters
This highlights the systemic impact of severe skin conditions on pediatric development and validates the use of targeted biologics for broader health benefits.
edited by Gaby Clark , reviewed by Andrew Zinin
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Credit: Tatiana Syrikova from Pexels New research from Trinity College Dublin has documented the significant impact of severe eczema on a child's height and shown, for the first time in a controlled study, that the right treatment can help improve growth.
The study investigating the effect of a drug commonly used to treat eczema, also known as atopic dermatitis (AD), has been published in the peer-reviewed Journal of the American Academy of Dermatology . The study of 123 children focused on growth and bone biomarkers in 6- to 11-year-olds with severe eczema.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in